Use access key #2 to skip to page content.
$4.77 0.46 (10.67%)
7/8/2008 4:00 PM

Dendreon Corp (DNDN)

CAPS Rating:
**

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

View All Commentary (DNDN)

Recs

0

Avatar deanafoulger (59.61) Submitted: 5/08/08 6:03 PM : Outperform Start Price: $5.06 DNDN Score: 2.36

This stock can be purchased at a great price and has the potential for great earnings. The company Dendreon is working to get a new drug approved for prostate cancer. It has already passed at least 3 FDA approvals.

Report this Post Replies: 0 | Reply

Featured Broker Partners